Literature DB >> 23733980

AIDS Drug Assistance Programs: managers confront uncertainty and need to adapt as the Affordable Care Act kicks in.

Erika G Martin1, Terence Meehan, Bruce R Schackman.   

Abstract

With the Affordable Care Act set to expand insurance coverage to millions more Americans next year, existing discretionary health programs that receive federal support might find themselves competing for funds as the health reform law is fully implemented. To assess the implications the Affordable Care Act might have for discretionary health programs, we focused on state AIDS Drug Assistance Programs, which provide free medications to low-income HIV patients. We conducted semistructured interviews with program managers from twenty-two states. Many of the managers predicted that their programs will change focus to provide "wrap-around services," such as helping newly insured clients finance out-of-pocket expenses, including copayments, deductibles, and premiums. Although program managers acknowledged that they must adapt to a changing environment, many said that they were overwhelmed by the complexity of the Affordable Care Act, and some expressed fear that state AIDS Drug Assistance Programs would be eliminated entirely. To remain viable, such programs must identify and justify the need for services in the context of the Affordable Care Act and receive sufficient political support and funding.

Entities:  

Keywords:  AIDS Drug Assistance Programs; AIDS/HIV; Health Reform; Organization And Delivery Of Care

Mesh:

Substances:

Year:  2013        PMID: 23733980     DOI: 10.1377/hlthaff.2012.0123

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  7 in total

1.  Early evidence from California on transitions to a reformed health insurance system for persons living with HIV/AIDS.

Authors:  Arleen A Leibowitz; Robbie Lester; Philip G Curtis; Kevin Farrell; Aaron Fox; Luke H Klipp; Jason Wise
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

2.  A qualitative study of underutilization of the AIDS drug assistance program.

Authors:  Kristin M Olson; Noah C Godwin; Sara Anne Wilkins; Michael J Mugavero; Linda D Moneyham; Larry Z Slater; James L Raper
Journal:  J Assoc Nurses AIDS Care       Date:  2014-02-04       Impact factor: 1.354

Review 3.  The Ryan White HIV/AIDS Program after the Patient Protection and Affordable Care Act full implementation: a critical review of predictions, evidence, and future directions.

Authors:  Tamar Ginossar; John Oetzel; Lindsay Van Meter; Andrew A Gans; Joel E Gallant
Journal:  Top Antivir Med       Date:  2019-09

Review 4.  Clinical outcomes of HIV care delivery models in the US: a systematic review.

Authors:  April D Kimmel; Erika G Martin; Hadiza Galadima; Rose S Bono; Ali Bonakdar Tehrani; John W Cyrus; Margaret Henderson; Kenneth A Freedberg; Alexander H Krist
Journal:  AIDS Care       Date:  2016-05-13

5.  PPACA and Low-Income People Living with HIV: 2014 Qualified Health Plan Enrollment in a Medicaid Nonexpansion State.

Authors:  Kathleen A McManus; Keanan M McGonigle; Carolyn L Engelhard; Rebecca Dillingham
Journal:  South Med J       Date:  2016-06       Impact factor: 0.954

6.  Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009.

Authors:  David B Hanna; Kate Buchacz; Kelly A Gebo; Nancy A Hessol; Michael A Horberg; Lisa P Jacobson; Gregory D Kirk; Mari M Kitahata; P Todd Korthuis; Richard D Moore; Sonia Napravnik; Pragna Patel; Michael J Silverberg; Timothy R Sterling; James H Willig; Ann Collier; Hasina Samji; Jennifer E Thorne; Keri N Althoff; Jeffrey N Martin; Benigno Rodriguez; Elizabeth A Stuart; Stephen J Gange
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

Review 7.  The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future.

Authors:  Emma Sophia Kay; D Scott Batey; Michael J Mugavero
Journal:  AIDS Res Ther       Date:  2016-11-08       Impact factor: 2.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.